{
    "2019-04-29": [
        [
            {
                "time": "2019-04-26",
                "original_text": "复星医药：一季度净利润同比增长0.92%",
                "features": {
                    "keywords": [
                        "复星医药",
                        "一季度",
                        "净利润",
                        "同比增长"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-26",
                "original_text": "复星医药(02196-HK)首季多赚近1%",
                "features": {
                    "keywords": [
                        "复星医药",
                        "首季",
                        "盈利增长"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-26",
                "original_text": "复星医药(02196.HK)一季度归母净利润增长0.92%至7.12亿元",
                "features": {
                    "keywords": [
                        "复星医药",
                        "一季度",
                        "归母净利润",
                        "增长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-26",
                "original_text": "复星医药(02196.HK)注册资本将减少至25.63亿元",
                "features": {
                    "keywords": [
                        "复星医药",
                        "注册资本",
                        "减少"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-26",
                "original_text": "医疗保健：带量采购执行情况超预期 荐9股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "带量采购",
                        "执行情况",
                        "超预期"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-26",
                "original_text": "后“年报季”聚焦高景气领域，关注业绩增长可持续性｜【光大医药·周报】",
                "features": {
                    "keywords": [
                        "年报季",
                        "高景气领域",
                        "业绩增长",
                        "可持续性"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-26",
                "original_text": "上证50指数涨超1%",
                "features": {
                    "keywords": [
                        "上证50指数",
                        "涨超1%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-26",
                "original_text": "【医药-复星医药(600196)】江琦、赵磊：公司点评：创新研发平台接连发力，报产国内首个曲妥珠单抗生物类似药",
                "features": {
                    "keywords": [
                        "复星医药",
                        "创新研发",
                        "曲妥珠单抗",
                        "生物类似药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-27",
                "original_text": "【山证医药】医药行业周报（20190427）：市场大幅调整，关注有基本面支撑的优质个股",
                "features": {
                    "keywords": [
                        "医药行业",
                        "周报",
                        "市场调整",
                        "基本面支撑",
                        "优质个股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}